Trials / Terminated
TerminatedNCT02987504
Study of Samalizumab in Patients With Advanced Cancer
A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients With Advanced Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, dose-escalation, Phase 1 study of intravenous (IV) samalizumab to determine its maximum tolerated dose (MTD), overall safety/tolerability, pharmacokinetic and pharmacodynamic parameters, and efficacy in participants with advanced cancer. The study was terminated for administrative reasons and not due to any safety concerns.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Samalizumab | Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration. |
Timeline
- Start date
- 2016-11-17
- Primary completion
- 2017-09-12
- Completion
- 2017-09-27
- First posted
- 2016-12-09
- Last updated
- 2018-07-18
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02987504. Inclusion in this directory is not an endorsement.